Bai Xiaojing, Jiang Yumei, Zhang Xinwei, Wang Meiyu, Tian Juanhua, Mu Lijun, Du Yuefeng
Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, People's Republic of China.
Oncology Research Lab, Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, Shaanxi 710061, People's Republic of China.
Cancer Manag Res. 2020 Aug 4;12:6821-6826. doi: 10.2147/CMAR.S257769. eCollection 2020.
The aim of this study was to explore the value of the prostate-specific antigen (PSA) levels, the ratio of free PSA to total PSA (fPSA/TPSA), the PSA density (PSAD), digital rectal examination (DRE), transrectal prostate ultrasound (TRUS), and multiparameter MRI (MP-MRI) in the differential diagnosis of benign prostatic hyperplasia (BPH) and prostate cancer (PCa).
From February 2016 to September 2019, data from 620 patients who underwent systematic transrectal ultrasound-guided prostate biopsy (STURS-PB) in our hospital were retrospectively collected, including the PSA levels, the fPSA/TPSA ratio, the PSAD, DRE, TRUS, MP-MRI, prostate volume, and other clinical data.
Among the 620 patients, 249 patients were in the PCa group, and 371 patients in the BPH group. The positive puncture rate was 40.16%. The positive predictive values of DRE, TRUS, mpMRI, and TPSA levels for PCa were 39.91%, 39.38%, 64.14%, and 41.57%, respectively; the sensitivity of these parameters was 37.35%, 51.41%, 74.69%, and 57.43%, respectively; and the specificity of these parameters was 62.26%, 46.90%, 71.97%, and 45.82%, respectively. When the TPSA concentration was in the range of 4-20 ng/mL, the positive puncture rate of STURS-PB was 23.18%, with a high rate of misdiagnosis. When the TPSA concentration was in the range of 4-20 ng/mL, the fPSA/TPSA ratio was 0.15, the PSAD was 0.16, the comprehensive evaluation of PCa was optimal (the sensitivity of these parameters was 88.85% and 84.09%, respectively; the specificity was 80.17% and 67.29%, respectively; the positive predictive value was 57.41% and 51.39%, respectively). When the TPSA concentration >4 ng/mL, the fPSA/TPSA ratio ≤0.15 and the PSAD ≥0.16, the sensitivity, specificity, and correctness index of the PCa and BPH diagnosis were 80.54%, 82.75%, and 67.07%, respectively.
When using DRE, TRUS, and MP-MRI to screen for PCa, MP-MRI has a relatively high sensitivity and specificity. Using these three thresholds (TPSA >4 ng/mL combined with an fPSA/TPSA ratio ≤0.15 and a PSAD ≥0.16) is significantly better than using TPSA levels alone for the differential diagnosis of PCa and BPH.
本研究旨在探讨前列腺特异性抗原(PSA)水平、游离PSA与总PSA比值(fPSA/TPSA)、PSA密度(PSAD)、直肠指检(DRE)、经直肠前列腺超声(TRUS)及多参数磁共振成像(MP-MRI)在良性前列腺增生(BPH)和前列腺癌(PCa)鉴别诊断中的价值。
回顾性收集2016年2月至2019年9月在我院接受系统性经直肠超声引导下前列腺穿刺活检(STURS-PB)的620例患者的数据,包括PSA水平、fPSA/TPSA比值、PSAD、DRE、TRUS、MP-MRI、前列腺体积及其他临床资料。
620例患者中,PCa组249例,BPH组371例。阳性穿刺率为40.16%。DRE、TRUS、mpMRI及TPSA水平对PCa的阳性预测值分别为39.91%、39.38%、64.14%和41.57%;这些参数的敏感性分别为37.35%、51.41%、74.69%和57.43%;特异性分别为62.26%、46.90%、71.97%和45.82%。当TPSA浓度在4 - 20 ng/mL范围内时,STURS-PB的阳性穿刺率为23.18%,误诊率较高。当TPSA浓度在4 - 20 ng/mL范围内时,fPSA/TPSA比值为0.15,PSAD为0.16,对PCa的综合评估最佳(这些参数的敏感性分别为88.85%和84.09%;特异性分别为80.17%和67.29%;阳性预测值分别为57.41%和5l .39%)。当TPSA浓度>4 ng/mL,fPSA/TPSA比值≤0.15且PSAD≥0.16时,PCa和BPH诊断的敏感性、特异性及正确指数分别为80.54%、82.75%和67.07%。
使用DRE、TRUS和MP-MRI筛查PCa时,MP-MRI具有相对较高的敏感性和特异性。使用这三个阈值(TPSA>4 ng/mL联合fPSA/TPSA比值≤0.15及PSAD≥0.16)进行PCa和BPH的鉴别诊断明显优于单独使用TPSA水平。